EarningsQ2 2026 Earnings Report
DE:CKX Q2 2026 EPS Results
Actual EPS-€0.18
Consensus EPS-€0.17
Beat/MissMissed by -<€0.01
One Year Ago EPS€1.83
DE:CKX Q2 2026 Revenue Results
Actual Revenue€43.67M
Expected Revenue€42.97M
Beat/MissBeat by +€708.11K
YoY Revenue Growth+7.74%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
DE:CKX Upcoming Earnings
CryoPort's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:CKX Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call communicated solid operational and financial progress: revenue growth (total and segment-level), expansion of clinical and commercial support, positive adjusted EBITDA and improved operating cash flow, product launches and facility expansions, and active digital/AI initiatives. Headwinds were largely cautious and strategic rather than acute — management reiterated guidance due to macro/geopolitical uncertainty, product growth is moderating YTD, China contribution remains small, and newer offerings like IntegriCell will take time to scale. On balance, the positive metrics and milestones outweigh the cautions, but the company remains prudent in guidance and execution timelines.Company Guidance
Total Revenue and Life Science Services Growth
Total revenue of $49.0 million in Q2 2026; Life Science Services revenue grew 15% year-over-year and represented 57% of total revenue, with biostorage and bioservices driving a 25% year-over-year increase.
Commercial and Clinical Support Momentum
Revenue supporting commercial cell and gene therapies grew 9% to $9.4 million (services portion grew 26% YoY); revenue supporting clinical trials increased 12% to $13.4 million. Total clinical trials supported reached 779 (net +51 YoY) including 94 Phase III trials; Cryoport supports ~70% of the industry’s trials and now supports 22 commercial therapies. Client Orca Bio received FDA approval for TREGZI.
Improved Profitability and Cash Generation
Adjusted EBITDA from continuing operations improved by $1.3 million year-over-year to positive adjusted EBITDA of $0.4 million for the quarter. Operating cash flow in H1 2026 was approximately $5 million (a $17 million improvement versus H1 2025), demonstrating stronger cash generation.
Life Science Products and MVE Performance
MVE Biological Solutions continued strong demand and acted as a consistent cash flow generator; MVE began shipping new products including the Fusion 811 self-regenerating cryogenic freezer. Production in China started in Q2 with first shipments of HE and Open Top models featuring CryoVerse Connect.
Operational Expansion and Facility Launches
IntegriCell cryopreservation services established clinical processes in Houston and Liège; selected by Verismo Therapeutics to support two KIR-CAR T-cell programs. Two new global supply chain centers (Paris and Santa Ana, CA) scheduled to open in Q4 2026, expanding global temperature-controlled network.
Affirmed Full-Year Guidance and Near-Term Regulatory Catalysts
Management affirmed FY2026 revenue guidance of $192 million to $196 million. For the remainder of 2026 management expects approximately 11 potential BLA/MAA filings, five additional therapy approvals, and one label/geographic expansion.
Digital Transformation and AI Adoption
Progress on digital initiatives including meaningful machine learning applications and enterprise-approved generative AI tools; management reports measurable productivity gains and use of AI to automate routine tasks, analyze large datasets, and expedite decision-making.
DE:CKX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed